Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before TAVI (PRESAR-HF)

University Hospital, Clermont-Ferrand

Status: Unknown

Conditions: Chronic Heart Failure; Sarcopenia

Treatments: Diagnostic Test: Assessment of sarcopenia prevalence

Study type: Interventional

Funder types: Other

Identifiers

NCT03153774

CHU-324

2014-A00938-39 (Other Identifier)

Details and patient eligibility

About

The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.

The loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. The purpose was to identify in these patients signs of sarcopenia for a better management.

Full description

Age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. The concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the "anabolic resistance", affecting the muscular fibers type II. In fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. The diagnosis is assessed by the weak muscle mass and the muscle strength and function. A description of these muscle parameters has been described in a study of 200 patients with NYHA class II-III and showed that 19,5 % have a decrease in muscle mass. They also showed that these patients have a lower functional ability. These findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Major patients (>18 years)
• Men or women
• Hospitalized in pre- trans aortic valvular implantation assessment in the cardiology department of the university hospital centre of Clermont-Ferrand or
• Patients with chronic heart failure in charge in the hospital of Clermont-Ferrand or convalescence in the pneumocardiological clinic of Durtol

Exclusion criteria

• Patient not affiliated to social security
• Inability to understand the information consent letter
• Not having signed informed consent
• Has a mental or legal incapacitation and is unable to provide informed consent.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

300 participants in 2 patient groups

Heart failure patients

Experimental group

Description:

The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.

Treatment:

Diagnostic Test: Assessment of sarcopenia prevalence

TAVI patients

Experimental group

Description:

The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.

Treatment:

Diagnostic Test: Assessment of sarcopenia prevalence